EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pancreatic enzyme replacement therapy in advanced adenocarcinoma of the pancreas improved overall survival: a retrospective, single institution study

Vincent J Picozzi iD, Margaret T Mandelson, Anas Najjar, Moming Li, Diala E Harb, Jens J Kort

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Vincent J Picozzi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Virginia Mason Hospital and Medical Center, Seattle, WA 98111, United States. Hauptthemen laut MEDLINE: Enzyme Replacement Therapy, Pancreatic Neoplasms, Adenocarcinoma, Carcinoma, Pancreatic Ductal. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Weight loss and exocrine pancreatic insufficiency are common in advanced pancreatic ductal adenocarcinoma (PDAC) and are associated with adverse outcomes. However, there is limited evidence on the impact of pancreatic enzyme replacement therapy (PERT) in patients with advanced PDAC. Patients and methods We retrospectively studied 501 patients with advanced PDAC and exocrine pancreatic insufficiency from the Virginia Mason Pancreas Cancer Program Data Resource treated between 2010 and 2019 with first-line chemotherapy. Clinical outcomes were compared between those who received PERT and those who did not at 8 weeks after chemotherapy start.

Results

In total 188 (38%) patients received PERT; 313 patients (62%) did not. PERT patients experienced less weight loss (–1.5 vs –2.5 kg, P = .04), less decline in the prognostic nutrition index −1.9 vs −3.0, P = .01), and a greater reduction in the additive score of the Patient-Generated Subjective Global Assessment (–8.4 vs –-6.0, P = .02). Importantly, median (95% CI) overall survival (OS) was significantly longer in the PERT vs non-PERT group (17.1 months vs 12.5 months, respectively P = .001), and the adjusted hazards ratio indicated superior median OS in patients prescribed PERT (HR = 0.73, P < .001).

Conclusions

Our findings suggest that treatment of exocrine pancreatic insufficiency (EPI) in advanced PDAC is associated with improvements in nutrition and overall survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enzyme Replacement TherapyPancreatic NeoplasmsAdenocarcinomaCarcinoma, Pancreatic DuctalExocrine Pancreatic InsufficiencyHumansMaleFemaleRetrospective StudiesMiddle AgedAgedAdultSurvival RateAged, 80 and overPrognosis

Stichwörter der Autor:innen

PERTadvanced pancreatic ductal adeno Caexocrine pancreatic insufficiencypancreatic cancer associated weight loss

Autor:innen und Institutionen

  • Virginia Mason Hospital and Medical Center, Seattle, WA 98111, United States.
  • Benaroya Research Institute, Seattle, WA 98101, United States.
  • Data and Statistical Sciences, AbbVie Inc., North Chicago, IL 60064, United States.
  • US Medical Affairs, AbbVie Inc., Mettawa, IL 60045, United States.

ORCID-Profile: Vincent J Picozzi

Förderung

  • AbbVie

Zitieren

APA

Picozzi, V. J., Mandelson, M. T., Najjar, A., Li, M., Harb, D. E., & Kort, J. J. (2025). Pancreatic enzyme replacement therapy in advanced adenocarcinoma of the pancreas improved overall survival: a retrospective, single institution study. The Oncologist. https://doi.org/10.1093/oncolo/oyaf014

Vancouver

Picozzi VJ, Mandelson MT, Najjar A, Li M, Harb DE, Kort JJ. Pancreatic enzyme replacement therapy in advanced adenocarcinoma of the pancreas improved overall survival: a retrospective, single institution study. The Oncologist. 2025. doi:10.1093/oncolo/oyaf014

BibTeX
@article{Picozzi2025,
  author = {Picozzi, Vincent J and Mandelson, Margaret T and Najjar, Anas and Li, Moming and Harb, Diala E and Kort, Jens J},
  title = {Pancreatic enzyme replacement therapy in advanced adenocarcinoma of the pancreas improved overall survival: a retrospective, single institution study},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf014}
}
Kostenlos starten →